Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 23 · below the Ichimoku cloud · RSI 38 · MACD below its signal · at its 52-week low
None of the 29 investors followed here reported a position in PREV.CN in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a PREV.CN trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for PREV.CN.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -20.0 | 0.0 | 0.0 | 0.0 | 0.0 | -25.0 | 0.0 | 66.7 | -20.0 | -25.0 | −40.0% | ||
| 2025 | 0.0 | 0.0 | 0.0 | 20.0 | 50.0 | -33.3 | 0.0 | 33.3 | -25.0 | 0.0 | -16.7 | 0.0 | 0.0% |
| 2024 | 0.0 | -20.0 | 25.0 | 0.0 | 20.0 | -16.7 | -20.0 | -25.0 | 0.0 | 33.3 | 0.0 | 25.0 | 0.0% |
| 2023 | 20.0 | 0.0 | -16.7 | 0.0 | 0.0 | 0.0 | 0.0 | 20.0 | 0.0 | -16.7 | 0.0 | 0.0 | 0.0% |
| 2022 | 0.0 | 0.0 | -20.0 | 50.0 | -16.7 | 0.0 | 0.0 | 0.0 | -20.0 | 0.0 | 25.0 | 0.0 | 0.0% |
| 2021 | -16.7 | 40.0 | -28.6 | 0.0 | 20.0 | -16.7 | 20.0 | 0.0 | -33.3 | 0.0 | 50.0 | -16.7 | −16.7% |
| 2020 | 100.0 | -50.0 | 0.0 | 66.7 | 20.0 | 83.3 | 9.1 | -33.3 | 0.0 | 0.0 | -12.5 | -14.3 | +100.0% |
| 2019 | 0.0 | -20.0 | 12.5 | 44.4 | -23.1 | -10.0 | -22.2 | 0.0 | -14.3 | -16.7 | -40.0 | 0.0 | −70.0% |
| 2018 | 10.6 | -16.3 | -13.8 | -30.7 | 34.6 | 14.3 | -56.2 | 14.3 | 237.5 | -29.6 | -26.3 | -28.6 | −46.8% |
| 2017 | 117.4 | -12.0 | 0.0 | 0.0 | 0.0 | -1.5 | 35.4 | -6.8 | -20.7 | -3.1 | -25.4 | +36.2% |
No analyst coverage for this instrument.
PreveCeutical Medical Inc., a health sciences company, engages in the development of options for preventive and curative therapies utilizing organic and nature identical products. Its research and development of preventive and therapeutic products derived from organic and nature-identical compounds; synthesized Nature Identical; Sol-Gel Nose-to-Brain delivery platform for Parkinson's disease; develops cannabinoid-based nose-to-brain delivery system for the relief of a various ailments, including pain, inflammation, seizures, and neurological disorders; peptide library synthesis, pharmacological evaluation, alongside pharmacokinetic assessment, and determinations in animal models of pain and inflammation; and non-addictive analgesic peptides for pain management. It also involved in licensing, branding, and marketing nutraceutical and wellness products; Sol-Gel platform; and peptide program. PreveCeutical Medical Inc. is headquartered in West Vancouver, Canada.
No recent headlines.